이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Neurocrine Biosciences 관리

관리 기준 확인 3/4

Neurocrine Biosciences' CEO는 Kevin Gorman, Jan2008 에 임명되었습니다 의 임기는 16.42 년입니다. 총 연간 보상은 $ 15.75M, 6% 로 구성됩니다. 6% 급여 및 94% 보너스(회사 주식 및 옵션 포함). 는 $ 67.34M 가치에 해당하는 회사 주식의 0.51% 직접 소유합니다. 67.34M. 경영진과 이사회의 평균 재임 기간은 각각 6.6 년과 11.5 년입니다.

주요 정보

Kevin Gorman

최고 경영자

US$15.8m

총 보상

CEO 급여 비율	6.0%
CEO 임기	16.4yrs
CEO 소유권	0.5%
경영진 평균 재임 기간	6.6yrs
이사회 평균 재임 기간	11.5yrs

최근 관리 업데이트

Recent updates

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

May 08

CEO 보상 분석

Kevin Gorman 의 보수는 Neurocrine Biosciences 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	US$370m
Dec 31 2023	US$16m	US$946k	US$250m
Sep 30 2023	n/a	n/a	US$191m
Jun 30 2023	n/a	n/a	US$176m
Mar 31 2023	n/a	n/a	US$64m
Dec 31 2022	US$12m	US$860k	US$155m
Sep 30 2022	n/a	n/a	US$58m
Jun 30 2022	n/a	n/a	US$12m
Mar 31 2022	n/a	n/a	US$71m
Dec 31 2021	US$14m	US$825k	US$90m
Sep 30 2021	n/a	n/a	US$445m
Jun 30 2021	n/a	n/a	US$365m
Mar 31 2021	n/a	n/a	US$402m
Dec 31 2020	US$14m	US$775k	US$407m
Sep 30 2020	n/a	n/a	US$93m
Jun 30 2020	n/a	n/a	US$205m
Mar 31 2020	n/a	n/a	US$177m
Dec 31 2019	US$9m	US$725k	US$37m
Sep 30 2019	n/a	n/a	US$21m
Jun 30 2019	n/a	n/a	US$18m
Mar 31 2019	n/a	n/a	-US$39m
Dec 31 2018	US$9m	US$675k	US$21m
Sep 30 2018	n/a	n/a	US$10m
Jun 30 2018	n/a	n/a	-US$52m
Mar 31 2018	n/a	n/a	-US$106m
Dec 31 2017	US$8m	US$640k	-US$143m

보상 대 시장: Kevin 의 총 보상 ($USD 15.75M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 13.50M ).

보상과 수익: Kevin 의 보상은 지난 1년 동안 20% 이상 증가했습니다.

CEO

Kevin Gorman (66 yo)

16.4yrs

테뉴어

US$15,750,812

보상

Dr. Kevin C. Gorman, Ph D., has been Chief Executive Officer of Neurocrine Biosciences, Inc. since January 2008 and served as its President since January 2008. Dr. Gorman is a Founder of Neurocrine Bioscie...

리더십 팀

이름	위치	테뉴어	보상	소유권
Kevin Gorman	CEO & Director	16.4yrs	US$15.75m	0.51% $ 69.9m
Matthew Abernethy	Chief Financial Officer	6.6yrs	US$6.06m	0.031% $ 4.3m
Jude Onyia	Chief Scientific Officer	2.6yrs	US$7.22m	0.013% $ 1.8m
Kyle Gano	Chief Business Development & Strategy Officer	13.4yrs	US$5.99m	0.13% $ 18.4m
Eiry Roberts	Chief Medical Officer	6.4yrs	US$5.87m	0.024% $ 3.2m
Jane Sorensen	Head of Investor Relations	no data	데이터 없음	데이터 없음
Darin Lippoldt	Chief Legal Officer & Corporate Secretary	9.7yrs	US$4.72m	0.039% $ 5.4m
Julie Cooke	Chief Human Resources Officer	6.8yrs	데이터 없음	0.018% $ 2.4m
Eric Benevich	Chief Commercial Officer	9.1yrs	US$5.81m	0.041% $ 5.5m
David Boyer	Chief Corporate Affairs Officer	4.8yrs	데이터 없음	0.0049% $ 664.3k
Ingrid Delaet	Chief Regulatory Officer	1.7yrs	데이터 없음	0.0075% $ 1.0m
Christopher O'Brien	Exclusive Consultant	6.4yrs	US$3.10m	데이터 없음

6.6yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: NBIX 의 관리팀은 노련하고 경험 (평균 재직 기간 6.6 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Kevin Gorman	CEO & Director	16.4yrs	US$15.75m	0.51% $ 69.9m
Christine Poon	Independent Director	less than a year	US$813.45k	0% $ 0
Richard Pops	Independent Director	26.2yrs	US$492.04k	0.031% $ 4.3m
Stephen Sherwin	Independent Director	25.2yrs	US$479.54k	0.026% $ 3.6m
William Rastetter	Independent Chairman of the Board	14.3yrs	US$495.04k	0.051% $ 7.0m
Gary Lyons	Independent Director	31.3yrs	US$460.11k	0.12% $ 16.2m
George Morrow	Independent Director	8.7yrs	US$479.54k	0.0042% $ 570.0k
Shalini Sharp	Independent Director	4.3yrs	US$497.11k	0.00099% $ 135.3k
Leslie Norwalk	Independent Director	4.8yrs	US$475.11k	0.00099% $ 135.3k
Johanna Mercier	Independent Director	3.2yrs	US$467.61k	0.0021% $ 285.7k

11.5yrs

평균 재임 기간

69yo

평균 연령

경험이 풍부한 이사회: NBIX 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 11.5 년).

Neurocrine Biosciences 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Independent Director notifies of intention to sell stock

Neurocrine Biosciences Announces CEO Changes

Neurocrine Biosciences Announces CEO Changes

Chief Financial Officer notifies of intention to sell stock

Insufficient new directors

Chief Commercial Officer notifies of intention to sell stock

Recent updates

Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine

Independent Director notifies of intention to sell stock

Neurocrine Biosciences Announces CEO Changes

Neurocrine Biosciences Announces CEO Changes

Neurocrine Biosciences, Inc. Announces Publication of Phase 3 KINECT-4 Post Hoc Analysis

Chief Financial Officer notifies of intention to sell stock

Neurocrine Biosciences, Inc. and Diurnal Ltd. Presents Baseline Data from the CAHtalyst Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024

Neurocrine Biosciences Presents CAHtalyst Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024

Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024

Consensus EPS estimates fall by 12%

Neurocrine Biosciences, Inc. Reaffirms Sales Guidance for the Full Year of 2024

Neurocrine Biosciences, Inc. Announces U.S. FDA Approval of INGREZZA SPRINKLE (valbenazine) Capsules

Insufficient new directors

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data

Neurocrine Biosciences, Inc. Launches What the C@H! Educational Initiative to Support Congenital Adrenal Hyperplasia Community

Neurocrine Biosciences, Inc. Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder

Chief Commercial Officer notifies of intention to sell stock

Neurocrine Biosciences, Inc., Annual General Meeting, May 22, 2024

Neurocrine Biosciences, Inc. Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

Independent Director notifies of intention to sell stock

Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

Independent Director notifies of intention to sell stock

New minor risk - Shareholder dilution

Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside

CEO & Director notifies of intention to sell stock

Neurocrine Biosciences, Inc. Provides Earnings Guidance for the Full Year of 2024

Insider notifies of intention to sell stock

Neurocrine Biosciences, Inc. to Report Fiscal Year 2023 Results on Feb 07, 2024

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Insider notifies of intention to sell stock

Chief Human Resources Officer notifies of intention to sell stock

Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt

Insider notifies of intention to sell stock

Sosei Heptares’ Partner Neurocrine Biosciences Confirms Its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical Studies

Neurocrine Biosciences, Inc. Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation

Neurocrine Biosciences, Inc. Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation

Neurocrine Biosciences, Inc. Reports Update on the Phase 2 Clinical Trial

Neurocrine Biosciences® Presents Ingrezza® (Valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated with Huntington's Disease Through Week 50 At Huntington Study Group 2023

Neurocrine Biosciences, Inc. Provides Sales Guidance for the Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Neurocrine Biosciences, Inc. to Report Q3, 2023 Results on Oct 31, 2023

Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts New Drug Application for Ingrezza®? (Valbenazine) Oral Granules Sprinkle Formulation

Independent Director notifies of intention to sell stock

Neurocrine Biosciences, Inc. Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)

Neurocrine Biosciences Inc. Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults

Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Independent Director notifies of intention to sell stock

Neurocrine Biosciences, Inc. Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders Demonstrating Comparable Improvement over Time in Tardive Dyskinesia Severity and Impact Following Treatment with INGREZZA (Valbenazine) Capsules

Neurocrine Biosciences, Inc. Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease

CEO & Director notifies of intention to sell stock

Neurocrine Biosciences, Inc. Announces FDA Approval of INGreZZA (valbenazine) Capsules for the Treatment of Chorea Associated with Huntington's Disease

Consensus EPS estimates increase by 22%

Neurocrine Biosciences, Inc. Reiterates Sales Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Neurocrine Biosciences, Inc. Announces Retirement of Eiry W. Roberts as Chief Medical Officer

Neurocrine Biosciences, Inc. to Report Q2, 2023 Results on Aug 01, 2023

We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease

Neurocrine Biosciences, Inc. Presents INGreZZA(R) (valbenazine) Capsules Data on Tardive Dyskinesia Improvement Regardless of Baseline Antipsychotic Use at 2023 Psych Congress Elevate

Neurocrine Biosciences, Inc. Announces Publication of Full KINECT(TM)-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in the Lancet Neurology

Neurocrine Biosciences, Inc. Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023

Consensus EPS estimates fall by 23%

Neurocrine Biosciences, Inc. Reiterates Sales Guidance for the Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Chief Human Resources Officer notifies of intention to sell stock